A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents

Lin, Xiaoqing Diana; Yuece, Birol; Li, Y.-Y.; Feng, Yuheng; Feng, Jia-yan; Yu, L.-Y.; Li, K.; Storr, Martin

doi:10.1111/j.1365-2982.2011.01742.x

Cited by 88 publications

(87 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports detected Gpr55 expression throughout the GI in both human (Henstridge et al 2011) and rodents (Ryberg et al 2007, Lin et al 2011, Schicho et al 2011, Schicho & Storr 2012, Li et al 2013. The gene expression pattern differs between areas, with higher levels in mouse jejunum and ileum than those in colon or stomach (Ryberg et al 2007).…”

Section: Distribution Of Gpr55 In Humans and Rodentsmentioning

confidence: 99%

“…The gene expression pattern differs between areas, with higher levels in mouse jejunum and ileum than those in colon or stomach (Ryberg et al 2007). Apart from being found in the submucosa (Lin et al 2011), Gpr55 is also expressed in neurons from the myenteric plexus (Lin et al 2011, Li et al 2013 pointing to a possible role of Gpr55 in GI physiological functions such as motility and secretion. Gpr55 mRNA has also been described in the liver of humans (Moreno-Navarrete et al 2012) and mice (Romero-Zerbo et al 2011); however, the hepatic function of the LPI/GPR55 system is still unknown.…”

Section: Distribution Of Gpr55 In Humans and Rodentsmentioning

confidence: 99%

“…Physiological studies show that activation of GPR55 resulted in the inhibition of the neurogenic contractions in the mouse intestine and are also involved in colon motility (Lin et al 2011, Li et al 2013. For instance, O-1602 reduced contractions in muscle strips from the colon and ileum, which slowed whole gut transit and colonic bead expulsion; effects that were reversed by CBD and did not occur in mice lacking GPR55 (Li et al 2013).…”

Section: Metabolic Actions Of Gpr55 In the Gastrointestinal (Gi) Tractmentioning

confidence: 99%

See 2 more Smart Citations

GPR55: a new promising target for metabolism?

Tudurí

Imbernón

Hernández-Bautista

et al. 2017

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

GPR55 is a G-protein-coupled receptor (GPCR) that has been identified as a new cannabinoid receptor. Given the wide localization of GPR55 in brain and peripheral tissues, this receptor has emerged as a regulator of multiple biological actions. Lysophosphatidylinositol (LPI) is generally accepted as the endogenous ligand of GPR55. In this review, we will focus on the role of GPR55 in energy balance and glucose metabolism. We will summarize its actions on feeding, nutrient partitioning, gastrointestinal motility and insulin secretion in preclinical models and the scarce data available in humans. The potential of GPR55 to become a new pharmaceutical target to treat obesity and type 2 diabetes, as well as the foreseeing difficulties are also discussed.

show abstract

Section: Distribution Of Gpr55 In Humans and Rodentsmentioning

confidence: 99%

Section: Distribution Of Gpr55 In Humans and Rodentsmentioning

confidence: 99%

Section: Metabolic Actions Of Gpr55 In the Gastrointestinal (Gi) Tractmentioning

confidence: 99%

See 1 more Smart Citation

GPR55: a new promising target for metabolism?

Tudurí

Imbernón

Hernández-Bautista

et al. 2017

Journal of Molecular Endocrinology

View full text Add to dashboard Cite

show abstract

“…31 The paraffin sections with pancreatic tissues were dewaxed by regular procedures and dipped in solution of 0.01-mol/L citric acid for 1 minute at 95-C, blocked with 5% goat serum for 30 minutes, and then incubated with rabbit anti-GPR55 polyclonal antibody (Cayman Chemical, Ann Arbor, Mich) overnight at 4-C at a dilution of 1:20. Sections were then followed by biotin-labeled goat antirabbit IgG for 15 minutes at 37-C, and horseradish peroxidaseYlabeled streptavidin (Jinqiao, Beijing, China) for 30 minutes at 37-C.…”

Section: Immunohistochemistrymentioning

confidence: 99%

Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-Induced Acute Pancreatitis in Mice

Feng²,

Li³

et al. 2013

Pancreas

View full text Add to dashboard Cite

Objectives: The anti-inflammatory effects of O-1602 and cannabidiol (CBD), the ligands of G proteinYcoupled receptor 55 (GPR55), on experimental acute pancreatitis (AP) were investigated.Methods: Acute pancreatitis was induced in C57BL mice by intraperitoneal injection of 50 Kg/kg cerulein hourly, with a total of 6 times. Drugs (O-1602, 10 mg/kg, or CBD, 0.5 mg/kg) were given by intraperitoneal injection 2 times at 30 minutes before the first injection and immediately before the fifth cerulein injection. At 3 hours after the last injection, the blood, the lungs, and the pancreas were harvested for the pancreatic enzyme activity, myeloperoxidase activity, and pro-inflammatory cytokines measurement; and the expressions of GPR55 mRNA and protein in the pancreas were detected.Results: Cannabidiol or O-1602 treatment significantly improved the pathological changes of mice with AP and decreased the enzyme activities, IL-6 and tumor necrosis factor > levels, and the myeloperoxidase activities in plasma and in the organ tissues. G proteinYcoupled receptor 55 mRNA and protein expressed in the pancreatic tissue, and the expressions were decreased in the mice with AP, and either CBD or O-1602 attenuated these changes to a certain extent.Conclusion: Cannabidiol and O-1602 showed anti-inflammatory effects in mice with AP and improved the expression of GPR55 in the pancreatic tissue as well.

show abstract

“…Thus, the release of endogenous CBs might be involved in the development of paralytic ileus, and different strategies aimed at normalizing endocannabinoid levels might be therapeutically useful in these conditions. In addition, CBD was also beneficial in a model of ileus in mice [77], maybe via a reduction in nitric oxide production [78]. …”

Section: Cb Effects On Altered Gi Motilitymentioning

confidence: 99%

The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility

et al. 2012

View full text Add to dashboard Cite

The marijuana plant Cannabis sp. and its derivatives and analogues, known as cannabinoids (CBs), induce many effects throughout the whole body. Herein we briefly review the gastrointestinal (GI) pharmacology of CBs, with special focus on motor function. Some drugs are available to treat nausea and emesis, and evidences in humans and animal models suggest that other GI motility alterations (gastro-oesophageal reflux, inflammatory bowel conditions or paralytic ileus) might benefit from modifications of the CB tone throughout the gut. However, central and peripheral (including GI) side effects may occur upon acute and chronic CB administration. Hopefully, the ongoing worldwide intense research on CBs will soon provide new, safer CB-based medicines.

show abstract

A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents

Abstract: G protein-coupled receptor 55 existed throughout the whole intestine of rats. O-1602 or CBD selectively normalized the motility disturbances. Possible mechanisms involved systemic anti-inflammation and the regulation of myoelectrical activity of the intestine.

Cited by 88 publications

References 37 publications

GPR55: a new promising target for metabolism?

GPR55: a new promising target for metabolism?

Anti-Inflammatory Role of Cannabidiol and O-1602 in Cerulein-Induced Acute Pancreatitis in Mice

The Gastrointestinal Pharmacology of Cannabinoids: Focus on Motility

Contact Info

Product

Resources

About